ANYSELaboratory Analytical InstrumentsFiscal year ends October 31
AGILENT TECHNOLOGIES, INC.
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 1, 2026
$169.90−3.07 (-1.77%)
Close on Oct 19, 2026
- Market cap
- $48.08B
- P/E (TTM)
- 33.5
- Dividend yield
- 0.58%
AGILENT TECHNOLOGIES, INC. revenue by segment
By business segment
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab | $786.00M | $759.00M | $758.00M | $755.00M | $744.00M | $713.00M | $696.00M | $706.00M | $691.00M | $664.00M | $686.00M | $1.49B | 41.9% | +5.6% |
| Life Sciences and Diagnostics Markets | $746.00M | $732.00M | $679.00M | $755.00M | $670.00M | $654.00M | $647.00M | $657.00M | $585.00M | $604.00M | $620.00M | – | 39.7% | +11.3% |
| Applied Markets | $346.00M | $344.00M | $361.00M | $351.00M | $324.00M | $301.00M | $338.00M | $338.00M | $302.00M | $305.00M | $352.00M | – | 18.4% | +6.8% |
| Diagnostics and Genomics | – | – | – | – | – | – | – | $442.00M | $385.00M | $417.00M | $407.00M | $445.00M | – | – |
| Life Sciences and Applied Markets | – | – | – | – | – | – | – | $833.00M | $782.00M | $754.00M | $846.00M | $839.00M | – | – |
| Operating income | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab | $270.00M | $242.00M | $240.00M | $246.00M | $248.00M | $231.00M | $221.00M | $239.00M | $248.00M | $216.00M | $222.00M | $504.00M | +8.9% |
| Life Sciences and Diagnostics Markets | $176.00M | $161.00M | $109.00M | $172.00M | $118.00M | $129.00M | $117.00M | $141.00M | $114.00M | $115.00M | $114.00M | – | +49.2% |
| Applied Markets | $86.00M | $80.00M | $93.00M | $87.00M | $71.00M | $59.00M | $84.00M | $86.00M | $70.00M | $64.00M | $92.00M | – | +21.1% |
| Diagnostics and Genomics | – | – | – | – | – | – | – | $94.00M | $70.00M | $86.00M | $70.00M | $101.00M | – |
| Life Sciences and Applied Markets | – | – | – | – | – | – | – | $233.00M | $222.00M | $186.00M | $236.00M | $240.00M | – |
By product or service
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $1.33B | $1.31B | $1.27B | $1.33B | $1.23B | $1.19B | $1.20B | $1.22B | $1.12B | $1.13B | $1.21B | $1.23B | 71.0% | +8.4% |
| Non-Instrumentation and Other | $1.24B | $1.22B | $1.14B | $1.21B | $1.14B | $1.12B | $1.06B | $1.08B | $1.02B | $1.03B | $1.03B | $1.04B | 65.8% | +8.4% |
| Instrumentation | $643.00M | $618.00M | $658.00M | $653.00M | $599.00M | $550.00M | $625.00M | $620.00M | $556.00M | $548.00M | $630.00M | $651.00M | 34.2% | +7.3% |
| Services and Other | $545.00M | $530.00M | $525.00M | $533.00M | $508.00M | $482.00M | $481.00M | $484.00M | $457.00M | $448.00M | $449.00M | $456.00M | 29.0% | +7.3% |
By region
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $761.00M | $764.00M | $678.00M | $776.00M | $683.00M | $678.00M | $669.00M | $680.00M | $626.00M | $637.00M | $630.00M | $702.00M | 40.5% | +11.4% |
| Asia Pacific | $613.00M | $553.00M | $602.00M | $559.00M | $563.00M | $548.00M | $549.00M | $567.00M | $520.00M | $510.00M | $570.00M | $553.00M | 32.6% | +8.9% |
| Europe | $504.00M | $518.00M | $518.00M | $526.00M | $492.00M | $442.00M | $463.00M | $454.00M | $432.00M | $426.00M | $458.00M | $433.00M | 26.8% | +2.4% |
From the segment and revenue-disaggregation notes of Agilent Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.